Mankind Pharma Ltd (MANKIND) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- Management reaffirmed its ambition to grow its chronic therapies share to 50% of domestic pharma sales in 4-5 years, adding 100-200 bps annually.
- The company acquired a 70% stake in CAR-T firm Arms Cell Therapeutics, with an initial 48 crore funding commitment expected to last until FY28.
- Despite a strong 27.1% EBITDA margin in Q2, the full-year guidance was maintained at 25.5-26.5%, with R&D spend guided to the higher end near 3%.
Performance Overview
- Delivered strong operating performance with revenue increasing 17% and EBITDA growing 27.7% year-on-year.
- The domestic pharma business outperformed the Indian Pharmaceutical Market (IPM) with secondary sales growth of 15.7% versus IPM's 14.2%.
- Chronic therapies continued to scale, with their share of the domestic business (excluding Viatris) expanding by 80 basis points to 37.4%.
- International business showed robust momentum, growing 33% year-on-year, driven by strength in both Mankind's own portfolio and the acquired Viatris (BSV) specialty brands.
- Consumer healthcare performance was soft, impacted by slower category offtake, although the e-commerce channel for this segment grew by 35%.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.